Engage Biologics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has completed the acquisition of Engage Biologics, a medical devices business in California, for $202 million. Eli Lilly acquisitions add a preclinical genetic medicine delivery platform designed to move DNA to target cells without viral payloads, using a “Tethosome” approach. Engage Biologics focuses on non-viral DNA delivery technology that combines lipid nanoparticles with an mRNA sequence to support nuclear transport, aiming to reduce AAV safety, dosing, manufacturing, and cost constraints. The platform acquisition is a strategic acquisition and healthcare M&A deal in CA acquisitions, structured as all-cash with an undisclosed upfront payment plus potential milestone-based payouts tied to research, development, and commercialization.